GlassScriptPhysician profile
Louis M Kleiman
NPI 1740363035
$742.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $91.48 · 2021: $11.74 · 2022: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $167.15 | 2019 | |
| Novo Nordisk INC | $150.42 | 2019-2022 | |
| Glaxosmithkline, LLC. | $77.94 | 2019-2020 | |
| Pfizer INC. | $58.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.52 | 2019 | |
| Astellas Pharma US INC | $46.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.88 | 2019-2020 | |
| Lilly USA, LLC | $35.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.80 | 2019 | |
| Abbott Laboratories | $24.96 | 2019 | |
| Allergan, INC. | $23.76 | 2020 | |
| Grt US Holding, INC. | $13.99 | 2020 | |
| Ibsa Pharma INC. | $12.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Kleiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.